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COMMENTARY
CYRI/ Fam49 Proteins Represent a New Class of Rac1 Interactors
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aCRUK Beatson Institute, University of Glasgow, Glasgow, UK; bDepartment of Cell and Developmental Biology, Vanderbilt University School
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ABSTRACT
Fam49 proteins, now referred to as CYRI (CYFIP-related Rac Interactor), are evolutionarily con-
served across many phyla. Their closest relative by amino acid sequence is CYFIP, as both proteins
contain a domain of unknown function DUF1394. We recently showed that CYRI and the DUF1394
can mediate binding to Rac1 and evidence is building to suggest that CYRI plays important roles
in cell migration, chemotaxis and pathogen entry into cells. Here we discuss how CYRI proteins fit
into the current framework of the control of actin dynamics by positive and negative feedback
loops containing Rac1, the Scar/WAVE Complex, the Arp2/3 Complex and branched actin. We also
provide data regarding the interaction between Rac1 and CYRI in an unbiassed mass spectrometry
screen for interactors of an active mutant of Rac1.
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Regulation of Arp2/3 driven actin assembly at
the lamellipodium
Orchestrated directional cell migration is fundamental for
multiple aspects of life; from development, wound healing
and immune responses to pathogens. At the core of cell
migration is the cells ability to rearrange its actin cytos-
keleton, which is driven predominantly by the Arp2/3
complex. During this process, extracellular cues trigger
intracellular signalling cascades resulting in the activation
of the small GTPases Rac1 and Cdc42 at the leading-edge
plasma membrane. In the case of Rac1, these signals
facilitate the interactions and subsequent activation of
the WAVE-regulatory complex (WRC). The WRC is
a pentameric complex composed of 5 members;
CYFIP1/2 (Sra/PIR121), NckAP1/2 (Hem-1/2),
WAVE1-3 (Scar1-3), HSPC300 (Brick1) and Abi1-3 [1].
Interaction with Rac1 causes conformational changes in
the complex, releasing the autoinhibited C-terminal
Arp2/3 binding domain of WAVE, which in turn acti-
vates the Arp2/3 complex [2–4] (Figure 1).
A recent study described two possible binding sites
for Rac1 on the WRC. These sites are referred to as
A and D- sites, with the D-site being first described by
Chen et al., 2017. The D-site has been described by
cryo-electron microscopy and is located within the
more C-terminal fragile X mental retardation protein
(FMRP) region of CYFIP [3,5]. Chen and colleagues
found that Rac1 binds to the D-site of CYFIP with
a greater affinity than the A-site alone. However, Rac1
binding to both regions on CYFIP is needed to cause
full activation of WRC [3]. The A- and D-sites were
confirmed to interact with active Rac1 within both
mammalian and Dictyostelium cells [5]. Moreover,
while the A-site was required for WRC activation, the
D-site was surprisingly dispensable for WRC activation
but necessary for proper lamellipodial formation and
functions, suggesting that both sites differentially con-
tribute to the activation and stability of the WRC for
lamellipodium dynamics [5].
The downstream activation of the Arp2/3 complex trig-
gers actin polymerisation at the leading edge and also the
formation of branched F-actin [2,6]. This generates broad,
flat membrane protrusions termed lamellipodia, which are
characteristic of cells migrating on flat rigid substrates. To
respond to directional cues rapidly, cells must have a fine-
tuned balance between protrusion and retraction to permit
steering and chages in direction. Through decades of
research, a pathway linking the Rho family GTPase Rac1,
theWRC and the Arp2/3 complex has been established for
lamellipodia generation and migration [7,8] and reviewed
in [9]. While the mechanisms required to activate actin
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polymerisation at the leading edge are still extensively
studied, how negative regulation allows plasticity and
retraction is less well understood. Gautreau and Krause
have highlighted the known positive and negative feedback
loops controlling branched actin assembly [9]. Negative
regulators of Arp2/3 complex have been described, such
as PICK1, Gadkin andArpin. However, only Arpin inhibits
the Arp2/3 complex at the lamellipodium, while Gadkin
and PICK1 play a role at surface endosome and clathrin-
coated pits, respectively [10–12]. Interestingly, some acti-
vators and inhibitors of the Arp2/3 complex co-localise at
membrane sub-compartments of the cell, such as Arpin
and WAVE at the lamellipodium, Gadkin and WASH at
endosomes and PICK1 and WASP at clathrin-coated pits
[13]. Gadkin and PICK1 both contain an acidic motif
resembling the tail of WASP-family proteins, but instead
of activating Arp2/3, they seem to be antagonistic. Arpin
was identified through a bioinformatics search for COOH-
terminal acidic A-motifs found in nucleation promoting
factors (NPFs). Arpin localises to the lamellipodia and acts
downstream of Rac1 to competitively inhibit binding of
WAVE to Arp2/3 by exposing the A-motif to Arp2/3 and
keeping it in an inactive confirmation [10,13]. This causes
a reduction in lamellipodia protrusion lifetime and direc-
tional persistence for migration [10], although it is dispen-
sable for chemotaxis [14].
A role for CYRI in membrane protrusions and
cell migration
All negative regulators of this pathway identified prior
to CYRI are inhibitors of the Arp2/3 complex, raising
the question: are there novel regulators at the level of
the WRC? Using a tagged version of the Dictyostelium
discoideum WRC subunit Nap1 (NckAP1 in human),
CYRI was identified by mass spectrometry through
a reversible formaldehyde cross-linked, GFP-trap pull-
down [15]. CYRI proteins are highly conserved through
evolution, where mammals have two isoforms, CYRI-A
and CYRI-B. The protein sequence of both CYRI iso-
forms comprise an N-terminal predicted alpha helix
with a concensus myristoylation site, followed by
a domain of unknown function 1394 (DUF1394)
domain, which has sequence homology to the WRC
subunit CYFIP1. The Rac1 binding A-site in CYFIP1
resides in the DUF1394, interacting specifically with
active forms of Rac1 but not Cdc42 or RhoA [15].
Depletion of CYRI-B and subsequent optogenetic acti-
vation of Rac1 promoted broader and less dynamic
lamellipodia, similar to the fried egg phenotype of
cells with constitutively active Rac1 as previously
described [16]. Conversely, overexpression of CYRI-B
resulted in cells shrinking in area and having unpro-
ductive protrusions. Localisation of CYRI-B to the lead-
ing edge of cells could only be observed in fixed assays
with a FLAG-tagged construct, which inhibited many
cells from forming lamellipodia. It is possible that lar-
ger C- or N-terminal tags such as GFP inhibit the
regulation of CYRI-B by interfering with N-terminal
myristoylation [15]. CYRI-B functions to restrict pro-
trusion lifetime and promote pseudopod splitting by
mimicking the Rac1-CYFIP interaction. It is therefore
required to regulate polarity and plasticity of protru-
sions for effective migration and chemotaxis [15].
Hans Meinhardt proposed that a minimal mathema-
tical model of cell migration could be made using
a global inhibitor, an activator and a local inhibitor
[17]. The local inhibitor needed to be smaller than the
activator (to diffuse more rapidly) and to be recruited
by the same signal as the activator. We postulate that
Figure 1. Negative regulation of actin polymerisation at the lamellipodium.
Actin polymerisation at the lamellipodium is activated through the Rac1-WRC-Arp2/3 cascade. Extracellular stimuli trigger GTP loading of
the small GTPase Rac1 and plasma membrane association. Activated Rac1 interacts with WRC through CYFIP1 at either or both the A- and
D-sites, releasing and presenting the VCA-domain of WAVE to the Arp2/3 complex. Arp2/3 triggers nucleation of branched F-actin at the
leading edge, generating a lamellipodium. Negative regulation of Arp2/3 can occur through the interaction with Arpin, which is activated by
Rac1. CYRI proteins compete with the WRC for active Rac1, thereby inhibiting Arp2/3 complex activation. The mechanism of activation of
CYRI proteins to constrain protrusions is still unknown. The activation cascade follows grey arrows, while inhibitors are shown in red
terminal lines.
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WRC and active Rac1 are the activators, while CYRI-B
plays the role of the local inhibitor by restricting Rac1’s
activity at the cell membrane [15] (Figure 1). While this
model is a good starting point to understand lamelli-
podial feedback loops, we are still left with further
questions surrounding the mechanisms of activation/
inactivation of CYRI.
Rac1-mediated pathways in cancer
Migration of tumour and associated cells is a key part of
cancer cell metastasis, which relies on the dynamic changes
of the actin cytoskeleton. Some studies have correlated
expression of components of the actin machinery with
cancer progression, but the importance of this is not clear
beyond a general correlation with increased actin dynamics
when cells are more mesenchymal and thus thought to be
more agrressive [13,18–20]. Reduced expression of Cyfip1
or NckAP1 has been linked to increased invasiveness, indi-
cating that they have the potential to act as tumour invasion
suppressors [21,22]. In vitro, silencing of either Cyfip1 or
NckAP1 in cancer cells migrating in 3D caused cells to
become more invasive due to increased reliance on an
N-Wasp driven Arp2/3-mediated migration [22].
However, in breast cancer cells, silencing of NckAP1 or
disrupting the Arp2/3 complex reduced invasion [23].
Moreover, following subcutaneous implant, there was no
difference in primary tumour volume, but a reduction in
the number of lung metastases of MDA-MB-231 cells [23],
indicating potential involvement of WRC in metastatic
dissemination.
Rac1 mediates activation of the WRC and resulting
actin polymerisation and can be hyperactivated in can-
cers. An activating mutant of Rac1 containing a proline
to serine change, Rac1P29S, was found in 9% of all sun-
exposed melanomas, placing it as one of the top 10
mutated genes (behind BRAF, NRAS, TP53, PTEN
and others) [24]. Rac1P29S shows a high GDP/GTP
exchange and thus is hyperactive. Similar to the con-
stitutively active Rac1Q61L, the Rac1P29S mutation
causes an increase in cell migration, membrane ruffles
and proliferation [25,26].
Before it was known to be a Rac1 interacting protein,
CYRI-B was highlighted as being highly expressed in
pancreatic cancer [27]. CYRI-B knockdown PDAC cells
were injected in the tail vein of immunocompromised
mice, resulting in increased lung colonisation and
enhanced growth compared with control cells [27]. This
may be due to enhanced Rac1 activity in CYRI-B knock-
out cells [15]. Rac1 has previously been implicated in
pancreatic cancer progression [28] and is thought to
regulate actin localisation and dynamics during dysplastic
changes in precancerous regions of pancreas as well [29].
In summary, disrupting the regulation of Rac1 signaling
and actin dynamicsmay drive the invasiveness and spread
of various cancers and the role of CYRI in this process
warrants further study.
Beyond actin dynamics
Chattaragada et al., found that silencing of CYRI-B in
PDAC cells lead to an increase in mitochondrial O2
− levels,
resulting in stress due to reactive oxidative species (ROS).
This rise in ROS levels was linked to enhanced tumour cell
proliferation and invasiveness [27]. In neutrophils, activa-
tion of Rac1 is well known to enhance superoxide produc-
tion via direct binding to the phagocyte oxidase complex
PHOX [30,31]. However, in other cell types, NOX plays the
role of PHOX and its regulation is much less well under-
stood [31,32]. It is possible that higher levels of Rac1
activity in CYRI knockout cells leads to activation of
NOX and thus induces greater superoxide production
observed by Chattaragada and colleagues [27].
Alternatively, Rac1 has been localised to the mitochondrial
membrane and is implicated in maintenance of superoxide
production homeostasis through its interaction with BCL-
2 [33]. Inhibiting the BCL-2-Rac1 interaction in lymphoma
cells, decreased themitochondrial O2
− levels and lead to the
triggering of apoptosis [33]. Furthermore, Chattaragada
et al. reported mitochondrial localisation of CYRI-B [27];
although we could not confirm this observation either in
mammalian cells or Dictyostelium thus far [15]. It remains
for the future to discover the mechanism by which CYRI
may impact on superoxide production and whether this is
related to Rac1 control of NOX or mitochondrial ROS
production.
Additionally, Yuki et al. [34] report that CYRI-B
restricts Salmonella infection in mice, as they identified
CYRI in a screen for novel genes that when mutated
affected susceptibility to infection. This suggests
a possible immune function for CYRI-B, possibly at the
level of bacterial uptake, which requires engagement of the
actin cytoskeletal machinery and Rac1 activation [34].
They further show in this study that CYRI-B can be
destroyed by ubiquitination downstreamof Rac1 activation
by the Salmonella effector SopE, suggesting interesting
possibilities for regulation of CYRI-B in cells [34].
Proteins that bind specifically to active Rac1
CYRI-B interacts with active forms of Rac1, such as
Rac1P29S, Rac1Q61L [15,34] and interestingly appears
to show increased affinity to double mutant
Rac1P29S/Q61L [15]. Rac1P29S/Q61L was first described
by Chen and colleagues [3] but is not a naturally
occurring mutation (to our knowledge). It is
114 J. A. WHITELAW ET AL.
unclear how this double mutation affects Rac1
structurally, including GTP binding or hydrolysis.
We speculated that this mutant might have higher
affinity for DUF1394 domains, since we and Chen
both found enhanced binding to CYRI and CYFIP.
To test whether any other motifs or proteins were
preferred by Rac1P29S/Q61L over the more conven-
tional single mutation Rac1Q61L, we transfected cells
with either GFP, GFP-Rac1Q61L or GFP-Rac1P29S/
Q61L (Figure 2A) and used GFP-trap and mass spec-
trometry to compare binding partners. We retrieved
many known Rac1-interacting proteins that were
grouped into Gene Ontology (GO)-terms (Figure
2B). Additionally many of the target genes were in
clusters around membrane-bound organelles such
as the nucleus and mitochondria (Figure 2B and
see also Supplementary Table 1). Details of proteins
interacting with either mutant active Rac1 protein
can be found in Supplementary Table 1 and the
data are available via ProteomeXchange with iden-
tifier PXD013941.
To our surprise, CYRI-B was the only protein
retrieved with a statistically significant ratio that
interacted preferentially with Rac1P29S/Q61L com-
pared to Rac1Q61L (Figure 2C). On the other hand,
ARHGDIA (also known as RhoGDI1) showed sig-
nificantly less binding to the double mutant
Rac1P29S/Q61L than Rac1Q61L. RhoGDI is the major
regulator of GDP-bound inactive Rho GTPases
Rac1Q61L [35] (Figure 2C). This could be a clue as
to why the double mutant Rac is more available for
binding to CYRI-B, but does not explain why we
did not retrieve CYFIP1 in this experiment nor why
CYRI-B and presumably the DUF1394 uniquely
prefers this mutant form of Rac1. Notably, the
NonO proteins, found to control nuclear actin and
transcription [36], also bound preferentially to
Rac1Q61L. Finally, we highlight proteins from our
screen that interact with Rac1 Q61L and Rac1 P29S/
Q61L at specific regions within the cell (Figure 2D).
This follows recent literature showing diverse func-
tions for Rac1 activity throughout the cell [37].
In summary, CYRI proteins are novel regulators
of lamellipodia dynamics through their interaction
with Rac1 at the DUF1394 domain. CYRI proteins
negatively regulate the activity of the WRC and
suppress lamellipodia spread and dynamics of pro-
trusions. Cells need CYRI proteins to maintain
plasticity and to allow leading edge actin dynamics
to be able to rapidly respond to changing environ-
ments. While CYRI’s role in cells is starting to
become clear, much remains to be learned about
the roles of CYRI proteins in healthy tissues, organ-
isms and in cancer.
Methods
Transfection and protein isolation
Cos-7 (chlorocebus sabeus fibroblast) cells grown at
37°C and 5% CO2, were transfected with either GFP,
GFP-Rac1Q61L (human) or GFP-Rac1P29S/Q61L using
Lipofectamine2000 (Invitrogen) following the manu-
facturer’s protocol. The transfected cells were left
overnight at 37°C, 5% CO2 and replated the next day
on laminin-coated dishes and incubated overnight.
The plates were washed twice in ice-cold PBS and
lysed in GFP-trap buffer (25mM Tris HCl, pH7.5,
100mM NaCl, 5mM MgCl2, 0.5% NP-40, containing
protease and phosphatase inhibitors). Around 1.5 mg
of lysates were incubated with GFP-Trap_A beads
(ChromoTek) for 2 hours at 4°C following the manu-
facturer’s protocol. Beads were washed three times with
Wash buffer (25mM Tris HCl, pH7.5, 100mM NaCl,
5mM MgCl2, containing protease and phosphatase
inhibitors). The beads were stored at −20°C in
a solution of 100 mM ammonium bicarbonate + 2 M
UREA Prior to digestion.
On-beads proteolytic digestion
Immunoprecipitations were performed in triplicate,
and purified proteins were digested on beads using
the method described in [38].
Liquid chromatography–mass spectrometry
Tryptic digests were obtained and separated by nanoscale
C18 reverse-phase liquid chromatography using an
EASY-nLC 1200 (Thermo Fisher Scientific) coupled to
an Orbitrap Q-Exactive HF mass spectrometer (Thermo
Fisher Scientific). The eluting peptide solutions were
introduced into the mass spectrometer via
a nanoelectrospray ion source (Sonation). The mass spec-
trometer was operated in positive ion mode and used in
data-dependent acquisition.
Data analysis
TheMS Raw data were processed withMaxQuant software
[39] and searched with Andromeda search engine [40],
querying both UniProt [41] Chlorocebus sabaeus (13/03/
2017; 19,228 entries) andHomo sapiens (09/07/2016; 92,939
entries) plus the sequence of GFP-Rac1 (Q61→L) and
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Figure 2. Screen for active Rac1 interacting proteins.
A) Cos7 cells transfected with GFP, GFP-Rac1Q61L or GFP-Rac1P29S/Q61L for immunoprecipitation with GFP-pulldown, Scale bar 25 μm. B) GO-
term analysis (Homo sapiens) to sort significantly enriched proteins that bound to both forms of active Rac1 compared to GFP into
categories based on number of hits. Adjusted p-values using the Benjamini False discovery rate (FDR) scoring shows significance of those
hits using a rainbow scale with p-value 0.05 highlighted. C) Volcano plot illustrating results from t-test applied on protein intensity
differences between the two Rac-1 mutants (GFP-Rac1Q61L and GFP-Rac1P29S/Q61L) measured in liquid chromatography–tandem mass
spectrometry experiments. The colour coding is based on density of the data points, the scale is indicated on the right, and the curved
line shows the 5% FDR. D) Schematic representation of a cell and the important regions of Rac1 activity based on the GO-term locations.
116 J. A. WHITELAW ET AL.
GFP-Rac1 (P29→S and Q61→L) construct used in the
experiment. Combined databases were searched assuming
the digestion enzyme trypsin allowing for twomiscleavages.
Methionine oxidation and N-terminal acetylation were
specified as variable modifications, and Cysteine carbami-
domethylation was specified as fixed modifications. The
peptide, protein and site false discovery rate (FDR) was
set to 1%. The common reverse and contaminant hits (as
defined in MaxQuant output) were removed. Only protein
groups identified with at least one uniquely assigned pep-
tide were used for the analysis. For label-free quantification,
proteins were quantified according to the label-free quanti-
fication algorithm available in MaxQuant [42]. Accurate
proteome-wide label-free quantification by delayed nor-
malization and maximal peptide ratio extraction, termed
MaxLFQ. Three independent replicates were generated per
condition (GFP control and two RAC-1 mutants used in
the immunoprecipitations), and significantly enriched pro-
teins were selected using a t-test based analysis (5% False
Discovery Rate).
Go-term analysis
Genes derived from mass spectrometry results were
scored for significance for both active Rac1 screens and
absent from GFP controls were then uploaded to DAVID
(Database for Annotation, Visualisation and Integrated
Discovery) v6.8 for GO-term themed searches following
the protocol described in [43]. We used Homo Sapiens as
the species as this closely relates to Chlorocebus sabaeus
but has more GO-terms available.
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